Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    FMR1
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Terminated The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry
Conditions: Fragile X Syndrome;   FMR1 Premutation;   Primary Ovairan Insufficiency;   Premature Ovarian Failure;   Premature Menopause
2 Terminated Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)
Condition: Pre-mutation on FMR1 Gene
Interventions: Other: examination of ocular movements;   Other: MATTIS test;   Other: UPDRS test;   Other: CRST test
3 Completed Examining Physiology and Brain Function in People With the Fragile X Premutation
Condition: Fragile X Premutation
4 Unknown  Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);   Other: Placebo
5 Unknown  Premature Ovarian Failure (Genetic and Physiopathologic Analysis)
Condition: Premature Ovarian Failure
6 Completed Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes
Conditions: Anxiety Disorders;   Child Developmental Disorders, Pervasive
7 Completed Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
Condition: Follicular Lymphoma
Interventions: Drug: FM+R;   Drug: Zevalin (Ibritumomab Tiuxetan)
8 Completed Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Rituximab;   Drug: Zevalin
9 Unknown  Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects
Condition: Obesity
Interventions: Dietary Supplement: THIAA;   Dietary Supplement: Placebo
10 Recruiting COAPT Clinical Trial
Conditions: Mitral Regurgitation;   Mitral Valve Regurgitation
Intervention: Device: MitraClip System
11 Unknown  VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study
Conditions: Mitral Valve Regurgitation;   Left Ventricular Dysfunction;   Heart Failure;   Mitral Insufficiency;   Mitral Incompetence;   Ischemic Heart Disease
Intervention: Device: Percutaneous mitral valve repair

Indicates status has not been verified in more than two years